Skip to main content
. 2021 Mar 15;131(6):e143765. doi: 10.1172/JCI143765

Figure 2. Targeting contextual synthetic lethalities in the TME.

Figure 2

(A) Low-dose antiangiogenesis therapy normalizes tumor vasculature. (B) Leaky vasculature enables affinity targeting of ECM components enriched in tumors. (C) Small-molecule drugs educate myeloid cells to antitumor phenotypes by differentiation or repolarization. Nanoparticle (NP) encapsulation improves delivery to phagocytes. (D) Enzymatic hydrolysis of ECM or inhibition of CAFs debulks tumor ECM, normalizing tumor structure and vascularity.